Physician
Ridgecrest Regional Hospital
Ridgecrest Regional Hospital was paid $10.24M by Medicaid between Jan 2018 and Dec 2024, across 246 billing codes. Its largest line is 0202U, Oncology (prostate), multianalyte, gene expression profiling — 12% of everything it billed.
33Billing provider infoRIDGECREST REGIONAL HOSPITAL
RIDGECREST, CA 93555
RIDGECREST, CA 93555
33aNPI1447253125assigned 05/24/2005
33bProvider typeEmergency Medicine Physician
28Total paid$10.24M
24GClaims334,695
24DCodes billed246
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in California
Rank by total paid#55 of 988
Median peer was paid$32K
This provider vs. median323×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 37,851 | $692K | |
| 2019 | 26,471 | $633K | |
| 2020 | 22,965 | $731K | |
| 2021 | 27,861 | $1.15M | |
| 2022 | 63,416 | $2.38M | |
| 2023 | 86,118 | $2.50M | |
| 2024incomplete | 70,013 | $2.14M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 12% | 4,081 | 3,955 | $1.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 11% | 10,894 | 10,424 | $1.12M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.4% | 15,803 | 14,435 | $961K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.8% | 14,430 | 14,139 | $898K |
| 0450 | Emergency room services | 7.4% | 11,277 | 9,631 | $753K |
| Z7502 | 6.5% | 17,648 | 17,121 | $661K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 4.6% | 4,853 | 4,468 | $475K |
| 80053 | Comprehensive metabolic panel | 2.1% | 24,419 | 22,368 | $215K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.1% | 925 | 900 | $213K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.9% | 3,832 | 3,613 | $190K |
| 87428 | 1.7% | 2,409 | 2,293 | $178K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 26,942 | 24,381 | $177K |
234 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 1,589 | $153K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.5% | 2,281 | $149K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.4% | 1,173 | $143K |
| Z7610 | 1.4% | 11,044 | $143K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.0% | 650 | $103K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,657 | $102K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 4,302 | $100K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,575 | $86K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,345 | $77K |
| 80061 | Lipid panel | <1% | 6,785 | $71K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,325 | $64K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,867 | $64K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,524 | $61K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,942 | $60K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,226 | $56K |
| 0270 | <1% | 4,766 | $55K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,638 | $52K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 673 | $50K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,536 | $49K |
| 83880 | <1% | 2,181 | $48K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,372 | $47K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 620 | $42K |
| 99070 | <1% | 9,881 | $40K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,249 | $39K |
| 84484 | <1% | 4,129 | $35K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 302 | $34K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,006 | $32K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,224 | $31K |
| 71250 | <1% | 326 | $31K | |
| 84439 | <1% | 4,505 | $31K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,195 | $30K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 399 | $29K |
| 73630 | <1% | 1,183 | $29K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 911 | $29K |
| 86710 | <1% | 2,009 | $28K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,464 | $28K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 552 | $27K |
| 81000 | <1% | 8,998 | $27K | |
| 77066 | Tomosynthesis, mammo | <1% | 259 | $25K |
| 84481 | <1% | 2,230 | $24K | |
| 73564 | <1% | 949 | $24K | |
| 87653 | <1% | 973 | $24K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,289 | $22K |
| 87081 | <1% | 3,389 | $22K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 440 | $22K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 291 | $20K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,928 | $20K |
| 83690 | <1% | 3,144 | $20K | |
| 93971 | <1% | 208 | $19K | |
| X3908 | <1% | 572 | $18K | |
| 76801 | <1% | 304 | $18K | |
| 73030 | <1% | 751 | $17K | |
| 73130 | <1% | 742 | $17K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,105 | $17K |
| 73610 | <1% | 684 | $17K | |
| 87510 | <1% | 956 | $15K | |
| 87480 | <1% | 956 | $15K | |
| 73110 | <1% | 558 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,860 | $13K |
| 85610 | <1% | 4,389 | $13K | |
| 93017 | <1% | 300 | $13K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 67 | $13K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 439 | $12K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 63 | $12K |
| 87186 | <1% | 1,616 | $12K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,524 | $11K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 40 | $11K |
| 80074 | <1% | 344 | $10K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,198 | $10K |
| J3490 | Unclassified drugs | <1% | 1,038 | $10K |
| 87660 | <1% | 613 | $9K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 386 | $9K |
| 86703 | <1% | 849 | $9K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 119 | $9K |
| 76830 | Ultrasound, transvaginal | <1% | 101 | $9K |
| 84703 | <1% | 717 | $9K | |
| 83735 | <1% | 1,834 | $9K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 128 | $9K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 149 | $9K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 997 | $9K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 656 | $8K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 215 | $8K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 694 | $7K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 334 | $7K |
| 86140 | <1% | 1,656 | $7K | |
| 76641 | <1% | 98 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 448 | $7K |
| Q3014 | Telehealth originating site facility fee | <1% | 418 | $7K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 212 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 258 | $7K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 109 | $6K |
| 85730 | <1% | 1,297 | $6K | |
| 72110 | <1% | 184 | $6K | |
| 84403 | <1% | 376 | $6K | |
| 83605 | <1% | 636 | $6K | |
| 82043 | <1% | 1,252 | $5K | |
| 85378 | <1% | 908 | $5K | |
| 73502 | <1% | 161 | $5K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,020 | $5K |
| 99499 | <1% | 101 | $5K | |
| 82550 | <1% | 1,058 | $5K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 25 | $4K |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | <1% | 75 | $4K |
| A4217 | Sterile water/saline, 500 ml | <1% | 626 | $4K |
| 86803 | <1% | 405 | $4K | |
| 93016 | <1% | 195 | $4K | |
| 87899 | <1% | 841 | $4K | |
| 93227 | <1% | 199 | $4K | |
| 82607 | <1% | 397 | $4K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 124 | $4K |
| 83550 | <1% | 689 | $4K | |
| 83540 | <1% | 769 | $3K | |
| X3910 | <1% | 343 | $3K | |
| 97161 | <1% | 46 | $3K | |
| 86592 | <1% | 988 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 450 | $3K |
| 81514 | <1% | 12 | $3K | |
| 85651 | <1% | 1,072 | $3K | |
| 81003 | <1% | 871 | $3K | |
| 72100 | <1% | 121 | $3K | |
| 82728 | <1% | 390 | $3K | |
| 59025 | Fetal non-stress test | <1% | 274 | $3K |
| 86850 | <1% | 1,028 | $3K | |
| 87806 | <1% | 84 | $3K | |
| 86901 | <1% | 1,069 | $3K | |
| 72131 | <1% | 25 | $3K | |
| 87340 | <1% | 342 | $2K | |
| 86762 | <1% | 261 | $2K | |
| 99460 | <1% | 34 | $2K | |
| 70486 | <1% | 13 | $2K | |
| 86900 | <1% | 1,041 | $2K | |
| 93296 | <1% | 100 | $2K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 375 | $2K |
| 93224 | <1% | 14 | $2K | |
| 87040 | <1% | 139 | $2K | |
| 0760 | <1% | 97 | $2K | |
| 82652 | <1% | 85 | $2K | |
| 84702 | <1% | 54 | $2K | |
| 93225 | <1% | 69 | $2K | |
| 0250 | <1% | 30 | $2K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 61 | $2K |
| 73080 | <1% | 86 | $2K | |
| 76536 | <1% | 40 | $2K | |
| 83655 | <1% | 258 | $2K | |
| 93226 | <1% | 45 | $2K | |
| Z7506 | <1% | 13 | $2K | |
| 86787 | <1% | 256 | $2K | |
| 93350 | <1% | 34 | $2K | |
| 83874 | <1% | 287 | $2K | |
| 82553 | <1% | 313 | $2K | |
| 86003 | <1% | 154 | $2K | |
| 72141 | <1% | 12 | $2K | |
| 84550 | <1% | 457 | $2K | |
| 93018 | <1% | 107 | $2K | |
| 87807 | <1% | 167 | $2K | |
| 99223 | Prolong inpt eval add15 m | <1% | 25 | $1K |
| 84100 | <1% | 418 | $1K | |
| 86038 | <1% | 318 | $1K | |
| 92551 | <1% | 108 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 126 | $1K |
| 84152 | <1% | 99 | $1K | |
| 73140 | <1% | 27 | $1K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 384 | $1K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 164 | $1K |
| 87070 | <1% | 170 | $1K | |
| 59425 | <1% | 21 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 171 | $1K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 79 | $1K |
| 99177 | <1% | 44 | $1K | |
| Z1034 | <1% | 19 | $1K | |
| 01992 | <1% | 16 | $1K | |
| 90715 | <1% | 26 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 71 | $1K |
| 86480 | <1% | 29 | $1K | |
| 82670 | <1% | 56 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 70 | $895.62 |
| 97010 | <1% | 34 | $845.22 | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 13 | $839.50 |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 17 | $788.63 |
| 0710 | <1% | 26 | $775.33 | |
| 77003 | <1% | 68 | $772.49 | |
| X3920 | <1% | 15 | $749.55 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 235 | $684.36 |
| 82746 | <1% | 103 | $640.77 | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 15 | $593.25 |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 15 | $587.51 |
| 82088 | <1% | 26 | $576.00 | |
| 83001 | <1% | 70 | $569.36 | |
| 94060 | <1% | 25 | $548.41 | |
| 82150 | <1% | 94 | $542.24 | |
| 85018 | <1% | 275 | $531.41 | |
| 84244 | <1% | 26 | $504.00 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 25 | $486.15 |
| 97750 | <1% | 13 | $452.92 | |
| 84402 | <1% | 25 | $450.47 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 47 | $444.96 |
| 76775 | <1% | 14 | $434.55 | |
| 82947 | <1% | 141 | $421.89 | |
| 86376 | <1% | 41 | $414.02 | |
| 83615 | <1% | 87 | $390.84 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 68 | $375.43 |
| Z7512 | <1% | 13 | $339.69 | |
| 83002 | <1% | 38 | $333.19 | |
| 82962 | <1% | 84 | $327.71 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 31 | $324.38 |
| 93041 | <1% | 172 | $308.22 | |
| 86430 | <1% | 86 | $298.98 | |
| 94664 | <1% | 26 | $295.49 | |
| 84300 | <1% | 56 | $292.03 | |
| 87088 | <1% | 149 | $283.82 | |
| 80076 | <1% | 56 | $269.43 | |
| 84133 | <1% | 58 | $267.85 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,288 | $261.05 |
| 99173 | <1% | 83 | $257.88 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 90 | $227.46 |
| 84144 | <1% | 14 | $213.92 | |
| 73090 | <1% | 12 | $192.96 | |
| 74018 | <1% | 13 | $183.45 | |
| 90686 | <1% | 14 | $177.30 | |
| 86705 | <1% | 15 | $120.72 | |
| 86709 | <1% | 15 | $117.60 | |
| J2704 | Injection, propofol, 10 mg | <1% | 30 | $115.82 |
| 93288 | <1% | 12 | $115.48 | |
| 83718 | <1% | 14 | $78.40 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 16 | $67.26 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 14 | $62.34 |
| 85652 | <1% | 86 | $56.87 | |
| 87077 | <1% | 34 | $53.25 | |
| 82465 | <1% | 14 | $42.62 | |
| 0637 | <1% | 17 | $1.68 | |
| 80050 | General health panel | 0% | 431 | $0.00 |
| 0250R | 0% | 85 | $0.00 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 13 | $0.00 |
| 0270R | 0% | 1,088 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSUVER, JAMES (CEO)
| Provider | Location | Paid |
|---|---|---|
| Ridgecrest Regional Hospital | Ridgecrest, CA | $43.74M |
| Ridgecrest Regional Hospital | Ridgecrest, CA | $4.05M |
| Progressive Ambulance, INC. | Ridgecrest, CA | $3.26M |
| Ridgecrest Regional Hospital | Ridgecrest, CA | $2.28M |
| Ridgecrest Regional Hospital | Ridgecrest, CA | $1.85M |
| Ridgecrest Regional Hospital | Trona, CA | $31K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.